Healthcare Practitioners

Unlock better treatment outcomes for your patients

  • Inagene's tests reveal which medications and nutritional decisions could help improve your patients' treatment oucomes, based on their unique genetic profile.

  • Clear and actionable genetic insights to inform your treatment plans

Medication genetic testing

Drugs and doses that work well for one patient often don’t work (or cause unexpected side effects) for others, and this can be significantly influenced by genetics. Take depression medications. Only about one-third of those with depression respond well to the first drug prescribed, ⁵ but many spend weeks or months cycling through drugs and doses, enduring persistent symptoms and/or side effects.

Nutrigenomics testing

Studies show that DNA-based dietary advice can increase motivation, prevent diseases, and avoid food intolerances. Our nutrigenomics test allows you to work with patients to tune their diet based on their DNA. The test is provided in partnership with Nutrigenomix, a biotechnology company dedicated to advancing the role of nutrition in health and performance.

Our Products

Testing Experience

The test is a simple cheek swab

Step 1

Your patient swabs their cheek with our kit and mails it to our lab with the package provided.

Step 2
When results are ready, your patient can view and download their personalized insights report.

Step 3
Your patient can discuss the results with you and other healthcare providers to optimize their treatment plans.

The Inagene report

Inagene’s report is a personalized guide on how genetic information affects the body’s needs. It delivers clear recommendations to help make informed, personalized health decisions, avoid trial and error, prevent side effects, and find effective medications faster. 

  • Consider Alternatives
  • Consider Modified Approach
  • Use Standard Precautions
  • Use Standard Precautions/Preferred
See a sample report

The Nutrigenomix Report

The Nutrition and Fitness report from Nutrigenomix provides information to give you insights into your patients’ unique response to the foods, supplements and beverages they consume so they can make the best dietary choices. The Nutrigenomix report breaks down findings and recommendations into six sections:

  • Nutrient Metabolism
  • Food Intolerances and Sensitivities
  • Cardiometabolic Health
  • Weight Management and Body Composition
  • Eating Habits
  • Exercise Physiology, Fitness and Injury Risk
See a sample report

The Science

Our laboratory

Our pharmacogenetics testing is performed in our Toronto-based CLIA-accredited  laboratory. CLIA (Clinical Laboratory Improvement Amendments) ensures laboratories meet quality control standards, guaranteeing accurate results and that tests on human specimens perform as designed. Inagene also holds a Medical Device Establishment Licence (#9922) from Health Canada. Our cutting edge technology, the MassARRAY® System combines mass spectrometry, sensitive and robust chemistry, and advanced data analysis software.

Medications tested

Inagene offers comprehensive pharmacogenetic testing, providing insights into more than 150 medications prescribed for pain, mental health, cardiology, cancer, gastrointestinal health and more. If a medication isn't on our list, it's often because there hasn't been sufficient scientific study to establish genetic factors influencing an individual's response to that medication.

How we source our recommendations

The recommendations in Inagene's report are sourced from established expert pharmacogenetics consortia, and regulatory bodies. These recommendations are then paired with insights gleaned from your DNA profile to provide you with personalized insights that can help you feel better, sooner.

How is Inagene different?

We offer the most comprehensive test for pain, mental health, heart disease, and other conditions, analyzing more genes and variants than any other pharmacogenetics test in Canada. Unlike other tests, Inagene’s recommendations are backed by publicly available pharmacogenetic guidelines from well-recognized, government-funded bodies established over the past two decades in the USA, Europe, and Asia. We combine this science with insights from your patients’ DNA profile to provide personalized insights you can trust.

See the impact Inagene can make in real patient case studies

Review results of a recent pilot study (including real patient cases) demonstrating how Inagene’s test results can be applied to optimize outcomes for patients with chronic pain and/or mental health conditions.

Download case studies

  • How to get started

  • Referral form

    Fax or email a referral form with the patient’s information. Inagene takes care of contacting the patient, arranging payment, and ensuring the report is available to the patient and the healthcare provider.

    Consignment

    Order or stock test kits on consignment free of charge and sell them directly to your patients. Processing at Inagene’s lab triggers an invoice from Inagene to the clinic at a wholesale price.

    Promo codes

    Refer patients to order their kit at Inagene.com for home delivery using your unique promo code.

    Real-time order

    Charge patients for the test kit in store, and then order the test kit free-of-charge for delivery to the patients home. Processing at Inagene’s lab triggers an invoice from Inagene to the clinic at a wholesale price.

FAQ

How do I open a HCP Portal Account?

Go to patients.inagene.com, click on “Register” and follow the instructions provided. Make sure to select “Healthcare Provider” as your user type. Detailed instructions can also be found here.

How is patient privacy assured?

Patients must consent to the genetic testing being performed, and healthcare providers ordering/registering the test must indicate that they have the patient’s permission to order the test and that the patient has been provided with access to Inagene’s Privacy and Consent Policy. Healthcare providers sharing results with other HCPs are prompted to confirm that they have the patient’s consent to share access to the results. Patients can view who has access to their online report via the Access Overview and can remove access at any time.

How are results shared between the pharmacist/HCP and the patient?

Either the health care provider or their patient can register the test kit on the Inagene Portal using the unique 14-digit code found in the kit. During registration, you can choose to share results with another party by entering their name and email (e.g., the HCP can CC their patient). Both the person who registered the kit and the CC'd individual will receive notifications when results are available. Results can be shared later by selecting “Share/View Report Access” and adding new access. Individuals can view and manage who has access to their report and remove access if needed. Note that the 14-digit code can only be registered once. Sharing can be managed or removed through the report's sharing section.

What if health care providers or their patients have questions that I am unable to answer?

Frequently asked questions to support patient consults are available in the report portal and are updated regularly. The “chat” function is also readily accessible from within the portal system and questions will be forwarded as necessary to the Inagene team member best suited to answer the question. Questions can also be sent to info@inagene.com.

My patient wants to discuss Inagene tests with another member of their health care team before ordering. What information can they bring with them?

Download a Summary for Prescribers (with helpful links and Inagene contact info embedded) that can be provided to your patient to send/take to their prescriber.

  • References

    1. Pharmacogenetics at scale: An analysis of the UK Biobank
    2. Haerdtlein A, Debold E, Rottenkolber M, et al. Which Adverse Events and
      Which Drugs Are Implicated in Drug-Related Hospital Admissions? A
      Systematic Review and Meta-Analysis. J Clin Med. 2023;12(4):1320.
      Published 2023 Feb 7. doi:10.3390/jcm12041320
    3. Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347-356. doi:10.1016/S0140-6736(22)01841-4
    4. Arnone D, Omar O, Arora T, et al. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. Neurosci Biobehav Rev. 2023;144:104965. doi:10.1016/j.neubiorev.2022.104965
    5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term
      outcomes in depressed outpatients requiring one or several treatment
      steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
      doi:10.1176/ajp.2006.163.11.1905